MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Cytokinetics Inc

Aperta

SettoreSettore sanitario

60.36 1.19

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

59.52

Massimo

61.42

Metriche Chiave

By Trading Economics

Entrata

27M

-134M

Vendite

65M

67M

Margine di Profitto

-201.246

Dipendenti

498

EBITDA

28M

-108M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+34.02% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

2.9B

7.3B

Apertura precedente

59.17

Chiusura precedente

60.36

Notizie sul Sentiment di mercato

By Acuity

92%

8%

360 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Cytokinetics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 apr 2025, 09:30 UTC

Notizie principali

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Confronto tra pari

Modifica del prezzo

Cytokinetics Inc Previsione

Obiettivo di Prezzo

By TipRanks

34.02% in crescita

Previsioni per 12 mesi

Media 80.64 USD  34.02%

Alto 120 USD

Basso 41 USD

Basato su 18 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cytokinetics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

18 ratings

15

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

32.3 / 40.43Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

360 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
help-icon Live chat